Department of Radiation Oncology, University of Maryland School of Medicine, University of Maryland Medical Center, Baltimore, Maryland 21201, USA.
Curr Opin Oncol. 2010 May;22(3):257-62. doi: 10.1097/CCO.0b013e3283378c84.
This overview summarizes recent developments in radiation-based therapy for prostate cancer.
Radiation dose escalation continues to be validated as an effective strategy in prostate cancer. Adjuvant radiation therapy became the standard of care after long-term follow-up of the pivotal Southwest Oncology Group 8794 trial demonstrated an overall survival benefit in patients with pT3 disease or positive margin after prostatectomy. Strategies such as hypofractionation and stereotactic body radiation therapy are becoming more common but have yet to be validated in a large trial. New technologies such as Calypso 4D real-time tumor tracking and volumetric-modulated arc therapy promise to potentially increase cure rates and decrease toxicity due to increased accuracy of radiation delivery.
Radiation therapy continues to play a prominent role in the management of prostate cancer. However, new strategies and technologies such as hypofractionation, stereotactic body radiation therapy, volumetric-modulated arc therapy, and Calypso tumor tracking must be prospectively validated.
本文概述了前列腺癌放射治疗的最新进展。
放射剂量递增被证实是前列腺癌的一种有效治疗策略。在关键的西南肿瘤组 8794 试验的长期随访后，辅助放疗成为标准治疗方法，该试验显示前列腺切除术后 pT3 疾病或切缘阳性的患者有总生存获益。诸如少分割和立体定向体部放疗等策略越来越常见，但尚未在大型试验中得到验证。Calypso 4D 实时肿瘤跟踪和容积调强弧形治疗等新技术有望通过提高放射治疗的准确性，从而提高治愈率并降低毒性。
放射治疗在前列腺癌的治疗中仍然起着重要的作用。然而，少分割、立体定向体部放疗、容积调强弧形治疗和 Calypso 肿瘤跟踪等新策略和技术必须经过前瞻性验证。
